Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Current Pharmaceutical Design|April 12, 2002
NR2B selective NMDA receptor antagonistsSham S Nikam, Leonard T MeltzerBioorganic & Medicinal Chemistry Letters|February 26, 2004
Subtype selective NMDA receptor antagonists: evaluation of some novel alkynyl analoguesBrian E Kornberg, Sham S Nikam, Jon L Wright, et al.Current Opinion in Investigational Drugs (London, England : 2000)|January 10, 2008
Evolution of schizophrenia drugs: a focus on dopaminergic systemsSham S Nikam, Alok K AwasthiCurrent Opinion in Investigational Drugs (London, England : 2000)|January 10, 2008
Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challengesErik H F Wong, Sham S Nikam, Mohammed ShahidBioorganic & Medicinal Chemistry Letters|December 28, 2007
1-Aminoindanes as novel motif with potential atypical antipsychotic propertiesJames M Graham, Linda L Coughenour, Bridget M Barr, et al.Synapse (New York, N.Y.)|June 2, 2006
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptorsMarc Morissette, Mehdi Dridi, Frédéric Calon, et al.Journal of Molecular Neuroscience : MN|August 16, 2008
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesiasBazoumana Ouattara, Samah Belkhir, Marc Morissette, et al.Movement Disorders : Official Journal of the Movement Disorder Society|August 30, 2005
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalinMarc Morissette, Mehdi Dridi, Frédéric Calon, et al.Synapse (New York, N.Y.)|November 10, 2007
Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeysPershia Samadi, Marc Morissette, Fréderic Calon, et al.Journal of Medicinal Chemistry|February 7, 2003
Orally active analogues of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one: synthesis and pharmacological activityBastiaan J Venhuis, Durk Dijkstra, David J Wustrow, et al.Pageof 2